Published in Croat Med J on June 01, 2015
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
A monoclonal gammopathy precedes multiple myeloma in most patients. Blood (2009) 3.98
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology (1996) 2.28
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Screening panels for detection of monoclonal gammopathies. Clin Chem (2009) 2.05
Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem (2009) 1.99
Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol (2007) 1.86
Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol (2006) 1.81
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol (2007) 1.62
Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies. Clin Chem (2011) 1.57
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Multiple myeloma. J Natl Compr Canc Netw (2011) 1.28
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients. Leukemia (2012) 1.23
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia (2011) 1.16
Demonstration of changes in plasma cell subsets in multiple myeloma. Haematologica (2007) 1.15
Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia (2012) 1.08
Blood volume in monoclonal gammopathy. Blood (1977) 1.01
Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem (2009) 0.97
Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma. Br J Haematol (2013) 0.91
Heavy/Light-chain analysis of monoclonal gammopathies. Clin Chem (2009) 0.89
Prospective study of serum protein capillary zone electrophoresis and immunotyping of monoclonal proteins by immunosubtraction. Am J Clin Pathol (1998) 0.82
Association of plasma cell subsets in the bone marrow and free light chain concentrations in the serum of monoclonal gammopathy patients. J Clin Pathol (2012) 0.81
[Evaluation of the new Hevylite™ IgA assay for the diagnosis and follow-up of monoclonal gammopathies]. Ann Biol Clin (Paris) (2013) 0.79
Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst (2005) 3.09
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood (2008) 2.12
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol (2009) 1.41
[Gaucher disease - guidelines for diagnosis and management of adult patients]. Lijec Vjesn (2015) 1.38
[Radiologic imaging of primary bone lymphoma--a retrospective study]. Lijec Vjesn (2006) 1.38
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica (2012) 1.24
LightCycler SeptiFast assay as a tool for the rapid diagnosis of sepsis in patients during antimicrobial therapy. J Med Microbiol (2008) 1.16
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica (2007) 1.15
Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study. Croat Med J (2002) 1.13
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol (2013) 1.07
The European LeukemiaNet: achievements and perspectives. Haematologica (2010) 1.02
Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma. Coll Antropol (2010) 0.96
Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med (2011) 0.96
Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. Leuk Lymphoma (2011) 0.94
Hodgkin s disease with nephrotic syndrome as a complication of ulcerative colitis: case report. Croat Med J (2002) 0.89
Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. Ann Hematol (2009) 0.89
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol (2011) 0.89
Premature ageing of the immune system underlies immunodeficiency in ataxia telangiectasia. Clin Immunol (2011) 0.87
Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. Pediatr Blood Cancer (2010) 0.87
Correlations among age, cytokines, lymphocyte subtypes, and platelet counts in autoimmune thrombocytopenic purpura. Pediatr Blood Cancer (2006) 0.86
Nuclear phosphoinositide 3-kinase C2beta activation during G2/M phase of the cell cycle in HL-60 cells. Biochim Biophys Acta (2003) 0.86
Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. Leuk Res (2009) 0.85
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica (2010) 0.85
The activation of nuclear phosphoinositide 3-kinase C2beta in all-trans-retinoic acid-differentiated HL-60 cells. FEBS Lett (2002) 0.84
Successful reversal of anticoagulant effect of superwarfarin poisoning with recombinant activated factor VII. Blood Coagul Fibrinolysis (2005) 0.84
Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. Int Orthop (2011) 0.83
Biological features and outcome of biphenotypic acute leukemia: a case series. Hematol Oncol Stem Cell Ther (2010) 0.83
Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP. Pathol Oncol Res (2010) 0.83
Collection and composition of autologous peripheral blood stem cells graft in patients with acute myeloid leukemia: influence on hematopoietic recovery and outcome. Coll Antropol (2010) 0.82
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial. Ann Hematol (2014) 0.81
Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica (2010) 0.81
The cellular story of dishevelleds. Croat Med J (2014) 0.81
Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin Rheumatol (2006) 0.81
Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol (2009) 0.80
Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia. Acta Haematol (2011) 0.80
Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol (2011) 0.80
Management of Gaucher disease in a post-communist transitional health care system: Croatian experience. Croat Med J (2003) 0.80
Aberrant glycosylation of Igg heavy chain in multiple myeloma. Coll Antropol (2007) 0.80
Expression of bone morphogenetic proteins in stromal cells from human bone marrow long-term culture. J Histochem Cytochem (2004) 0.79
[Biphenotypic and bilineal acute leukemias]. Acta Med Croatica (2008) 0.79
Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation? Semin Hematol (2007) 0.79
Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. Croat Med J (2004) 0.78
Rhabdomyosarcoma with bone marrow infiltration mimicking hematologic neoplasia. Coll Antropol (2010) 0.78
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. Eur J Clin Invest (2012) 0.78
CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma. Clin Lymphoma Myeloma (2009) 0.78
Carboplatin resistant human laryngeal carcinoma cells are cross resistant to curcumin due to reduced curcumin accumulation. Toxicol In Vitro (2012) 0.78
Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study. Croat Med J (2002) 0.78
Large volume leukapheresis: Efficacy and safety of processing patient's total blood volume six times. Transfus Apher Sci (2011) 0.78
FNA based diagnosis of head and neck nodal lymphoma. Coll Antropol (2010) 0.77
Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. Onkologie (2005) 0.77
Apoptosis of leukemic cells: a case report. Coll Antropol (2010) 0.77
[Thrombophilia--inherited and acquired susceptibility to thrombosis]. Lijec Vjesn (2009) 0.77
ZAP-70 expression and proliferative activity in chronic lymphocytic leukemia. Leuk Lymphoma (2012) 0.77
[Diagnostic approach and therapy for cytomegalovirus (CMV) infection following allogeneic stem cell transplantation]. Lijec Vjesn (2012) 0.77
Erdheim-Chester disease and concomitant tuberculosis successfully treated with chemotherapy and long-term steroids. Coll Antropol (2007) 0.76
Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants. J Hematother Stem Cell Res (2002) 0.76
Hepatosplenic αβ T-cell lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant. Leuk Lymphoma (2012) 0.76
Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease? Croat Med J (2016) 0.75
High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease. Croat Med J (2016) 0.75
Chronic graft-vs-host disease in 2016: a major challenge and an opportunity. Croat Med J (2016) 0.75
Radiotherapy of primary cutaneous follicle center lymphoma: case report and review of literature. Radiat Oncol (2013) 0.75
The influence of tumor necrosis factor microsatellite polymorphisms on patient survival following hematopoietic stem cell transplantation. Croat Med J (2012) 0.75
Venous thromboembolism in Croatia - Croatian Cooperative Group for Hematologic Diseases (CROHEM) study. Croat Med J (2015) 0.75
Multiparameter flow cytometry is necessary for detection, characterization and diagnostics of composite mature B-cell lymphoproliferative neoplasms. Int J Hematol (2013) 0.75
Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity? Croat Med J (2016) 0.75
Successful treatment of diffuse large B-cell non-hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome. Clin Lymphoma Myeloma (2007) 0.75
Joint and fascial chronic graft-vs-host disease: correlations with clinical and laboratory parameters. Croat Med J (2016) 0.75
[90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab]. Lijec Vjesn (2006) 0.75
A search for a mutation of the Aiolos phosphorylation domain in lymphocytes from patients with leukemia. Haematologica (2007) 0.75